Диссертация (1174213), страница 46
Текст из файла (страница 46)
– 2009. - № 2(2). - Р. 100-6. doi:10.1161/CIRCIMAGING.108.795328.300. O'Brien EC. Clinical Characteristics, Oral Anticoagulation Patterns,and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From theOutcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBITAF I) Registry /O'Brien EC, Kim S, Thomas L, Fonarow GC, Kowey PR,Mahaffey KW, Gersh BJ, Piccini JP, Peterson ED // J Am Heart Assoc. – 2016. № 4;5(5). doi:10.1161/JAHA.115.002721.301.
Oh S. Vitamin K antagonist control in patients with atrial fibrillationin Asia compared with other regions of the world: Real-world data from theGARFIELD-AF registry /Oh S, Goto S, Accetta G, Angchaisuksiri P, Camm AJ,Cools F, Haas S, Kayani G, Koretsune Y, Lim TW, Misselwitz F, van Eickels M,Kakkar AK; GARFIELD-AF Investigators // Int J Cardiol. – 2016. - № 223. – Р.543-547. doi:10.1016/j.ijcard.2016.08.236.302. Okumura K. Effects of blood pressurelevelsoncasefatalityafteracutestroke /Okumura K, Ohya Y, Maehara A, Wakugami K, Iseki K//J Hypertens.
–2005. - №23(6). - Р.1217-1223.303. Oldgren J. Variations in cause and management of atrial fibrillation ina prospective registry of 15,400 emergency department patients in 46 countries:the RE-LY Atrial Fibrillation Registry /Oldgren J, Healey JS, Ezekowitz M,Commerford P, Avezum A, Pais P, et al. // Circulation. – 2014.
- №129. – Р.1568–76.304. Olesen JB. Risk factors for stroke and thromboembolism in relation toage among patients with atrial fibrillation: the Loire Valley Atrial FibrillationProject /Olesen JB, Fauchier L, Lane DA, et al. // Chest. – 2012. – 141. – Р. 147–153.305. Olesen JB. Validation of risk stratification schemes for predictingstroke and thromboembolism in patients with atrial fibrillation: nationwide cohortstudy /Olesen JB, Lip GY, Hansen ML et al. // BMJ. - 2011. - № 342. - P. d124.306.
Olesen JB. Stroke and bleeding in atrial fibrillation with chronickidney disease /Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA,Lindhardsen J, Gislason GH, Torp-Pedersen C // N Engl J Med. – 2012. - №367. –Р.625–635.307. Olesen JB. The value of the CHA2DS2-VASc score for refining strokerisk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: anationwide cohort study /Olesen JB, Torp-Pedersen C, Hansen ML, Lip G //Thromb Haemost. – 2012. -№ 107.
– Р. 1172–1179.308. Olsson LG. Atrial fibrillation and risk of clinical events in chronic heartfailure with and without left ventricular systolic dysfunction: results from theCandesartan in Heart failure-Assessment of Reduction in Mortality and morbidity(CHARM) program /Olsson LG, Swedberg K, Ducharme A, Granger CB,Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA // J Am Coll Cardiol. –2006.
- №47. – Р.1997–2004.265309. Overvad TF. Body mass index and adverse events in patients withincident atrial fibrillation /Overvad TF, Rasmussen LH, Skjoth F, Overvad K, LipGY, Larsen TB // Am J Med. – 2013. - №126. – Р.640.e649–617.310. Overvad TF. Duration of Diabetes Mellitus and Risk ofThromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort Study/Overvad TF, Skjoth F, Lip GY, Lane DA, Albertsen IE, Rasmussen LH, LarsenTB // Stroke. – 2015.
- №46. – Р.2168–2174.311. Pan X. Discontinuation among early users of apixaban, dabigatran,rivaroxaban or warfarin among atrial fibrillation patients newly initiated onanticoagulation therapy: tale of first 200 days /Pan X, Kachroo S, Liu X, KawabataH, Phatak H // Eur Heart J. – 2014. - №35(Abstract Supplement). – Р. 897.312. Patel MR. Rivaroxaban versus warfarin in nonvalvularatrial fibrillation/Patel MR, Mahaffey KW, Garg J, et al., for the ROCKET-AF Investigators // NEngl J Med. – 2011.
- № 365. – Р. 883-891.313. Peacock E. Adherence to Antihypertensive Therapy /Peacock E,Krousel-Wood M // Med Clin North Am. – 2017. - № 101(1). – Р.229-245.314. Perkovic V. Redefining blood-pressure targets – SPRINT starts themarathon /Perkovic V, Rodgers A // N.
Engl. J. Med. – 2015. - V. 373. - P. 2175–2178.315. Piccini JP. Outcomes registry for better informed treatment of atrialfibrillation: rationale and design of ORBIT-AF /Piccini JP, Fraulo ES, Ansell JE,Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, ThomasLE, Kong MH, Lopes RD, Mills RM, Peterson ED // Am Heart J.
– 2011. - №162(4). – Р.606-612.e1. doi: 10.1016/j.ahj.2011.07.001.316. Piccini JP. Renal dysfunction as a predictor of stroke and systemicembolism in patients with nonvalvular atrial fibrillation: validation of theR(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, directfactor Xa inhibition Compared with vitamin K antagonism for prevention of strokeand Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Riskfactors In Atrial fibrillation) study cohorts /Piccini JP, Stevens SR, Chang Y, et al.ROCKET AF Steering Committee and Investigators // Circulation. – 2013.
№127. – Р.224–32.317. Pisters R. A novel userfriendly score (HAS-BLED) to assess 1-yearrisk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey/Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. // Chest. –2010. - № 138.
– Р.1093–1100.318. Pokorney SD. Patients' time in therapeutic range on warfarin amongUS patients with atrial fibrillation: Results from ORBIT-AF registry /PokorneySD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, Singer DE,AnsellJ, Blanco RG, Gersh B, Mahaffey KW, Hylek EM, Go AS, Piccini JP, PetersonED; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation(ORBIT-AF) Investigators// Am Heart J.
– 2015. - №170(1). – Р.141-8, 148.e1.319. Potpara TS. The Patterns of Non-vitamin K Antagonist OralAnticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan266Countries: a Report from the BALKAN-AF Survey /Potpara TS, Trendafilova E,Dan GA, Goda A, Kusljugic Z, Manola S, Music L,Gjini V, Pojskic B, PopescuMI, Georgescu CA, Dimitrova ES, Kamenova D, Ekmeciu U, Mrsic D, NenezicA, Brusich S, Milanov S, Zeljkovic I, Lip GYH; BALKAN-AF Investigators//Adv Ther.
- 2017. - №34(8). – Р.2043-2057.320. Potter JF, Robinson TG, Ford GA, Mistri A, James M, ChernovaJ, Jagger C. Controlling hypertension and hypotension immediately post-stroke(CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. LancetNeurol. – 2009. - №8(1). - Р.48-56.321. Proietti M. 'Real-world' atrial fibrillation management in Europe:observations from the 2-year follow-up of the EURObservational ResearchProgramme-Atrial Fibrillation General Registry Pilot Phase /Proietti M, LarocheC, Opolski G, Maggioni AP, Boriani G, Lip GY; AF Gen Pilot Investigators //Europace. – 2016. - May 18.
– Р. pii: euw112.322. Qureshi AI. Intensive Blood-Pressure Lowering in Patients withAcute Cerebral Hemorrhage /Qureshi AI, Palesch YY, Barsan WG, Hanley DF,Hsu CY, Martin RL, Moy CS, Silbergleit R, Steiner T, Suarez JI, Toyoda K, WangY, Yamamoto H, Yoon BW; ATACH-2 Trial Investigators and the NeurologicalEmergency Treatment Trials Network // N Engl J Med.
– 2016. - №375(11). –Р.1033-43.323. Rash A. A randomised controlled trial of warfarin vs. aspirin for strokeprevention in octogenarians with atrial fibrillation (WASPO) /Rash A, Downes T,Portner R, et al. // Age Ageing. – 2007. - №36. – Р. 151–156.324. Reddy VY. Percutaneous left atrial appendage closure for strokeprophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of thePROTECT AF (Watchman Left Atrial Appendage System for Embolic Protectionin Patients with Atrial Fibrillation) Trial /Reddy VY, Doshi SK, Sievert H,Buchbinder M, Neuzil P, Huber K, Halperin JL, Holmes D // Circulation. – 2013.
№127. – Р.720–729.325. Renda G. Antithrombotic management of atrial fibrillation: follow-updata from the PREFER in AF registry /Renda G, Schilling R, Le Heuzey JY,Darius H, Zamorano JL, Schmitt J, De Caterina R, Kirchhof P // European HeartJournal. – 2016. - № 37 (Abstract Supplement). – Р. 494-495.326. Rizzo M. Autonomic dysfunction is associated with brief episodes ofatrial fibrillation in type 2 diabetes /Rizzo MR, Sasso FC, Marfella R, SiniscalchiM, Paolisso P, Carbonara O, Capoluongo MC, Lascar N, Pace C, Sardu C,Passavanti B, Barbieri M, Mauro C, Paolisso G // J Diabetes Complications. –2015. - №29. – Р.88–92.327. Robson J.
Improving anticoagulation in atrial fibrillation: observationalstudy in three primary care trusts /Robson J, Dostal I, Mathur R, et al. // TheBritish Journal of General Practice. – 2014. - №64(622). – Р.e275-e281.328. Rodriguez MA. Hypertensive crisis /Rodriguez MA, Kumar SK, DeCaro M // Cardiol Rev. - 2010. - №18(2). - Р. 102-107.267329.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
